Screener
ImmunityBio, Inc. IBRX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s enterprise value?
- ImmunityBio, Inc. (IBRX) reported enterprise value of $8.16B in Q1 2026.
- How has ImmunityBio, Inc.'s enterprise value changed year-over-year?
- ImmunityBio, Inc.'s enterprise value increased by 186.9% year-over-year, from $2.85B to $8.16B.
- What is the long-term trend for ImmunityBio, Inc.'s enterprise value?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s enterprise value has grown at a -15.2% compound annual growth rate (CAGR), from $5.08B to $2.23B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about ImmunityBio, Inc.'s enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude